Publikace detail

Comparison of Index pI50 of New Cholinesterase Inhibitors with Rivastigmine

Autoři: Zdražilová Pavla | Štěpánková Šárka | Komers Karel | Ventura Karel | Čegan Alexander

Rok: 2003

Druh publikace: ostatní - přednáška nebo poster

Název zdroje: PhandTA 7

Název nakladatele: University of Insbruck, Austria

Místo vydání:

Strana od-do:

Tituly:

Jazyk	Název	Abstrakt	Klíčová slova
cze	Srovnání indexu pI50 nových inhibitorů cholinesteráz s Rivastigminem a Galanthaminem		acetylcholinesterasa; butyrylcholinesterasa, karbamaty, karbazaty; Alzheimerova choroba
eng	Comparison of Index pI50 of New Cholinesterase Inhibitors with Rivastigmine	The aim of the research was to find a suitable inhibitor decreasing the concentration and/or activity of acetylcholine esterase (ACHE) and/or butyrylcholinesterase (BCHE) and to compare its inhibiting power with the drugs for Alzheimer disease (AD) treatment already in use. The inhibiting power of chosen carbamates and carbazates owing to the hydrolysis of acetylthiocholine by butyrylcholinesterase or acetylcholinesterase was tested. The force of every substance (I) inhibiting an enzyme can be approximately evaluated by its index pI50 , i.e. the negative logarithm of the concentration of I producing the 50% inhibition (pI50) of the enzyme activity under given conditions. For determination of pI50 the spectrophotometric Ellman´s method was used. Recently only four remedies for AD treatment with different inhibiting action are worldwide allowed, the most important of whom, rivastigmine (Exelon), is the cholinesterase carbamate inhibitor with dual effect on brain ACHE and brain BCHE. According to this knowledge we have focused our study to the N´-monoalkyl- of 3-N,N-diethylaminophenol (carbamates) and chlorine derivates of 2-phenoxycarbonyl?2-methylhydrazinium-chloride and 2-phenoxycarbonyl?1,2-dimethylhydrazinium-chloride (carbazates), which showed similar inhibiting action as rivastigmine. All tested substances showed anticholinesterase activity. The determined values of pI50 of the tested substances were compared with pI50 of the commercially used drugs for the Alzheimer disease treatment ? rivastigmine and galanthamine. According to the pI50 indices, the tested carbamates are equally or more effective inhibitors of the used esterases in comparison with the currently used drugs. But their pI50 values are not dramatically greater than pI50 of the compared drugs. The tested carbazates appeared, according to the same criteria, as less effective inhibitors of the used esterases than these drugs. The most active substances have inhibiting coefficient pI	acetylcholinesterasis, butyrylcholinesterasis; carbamates, carbazates, Alzheimer disease

Vyhledávání

Přihlášení pro studenty

Přihlášení pro zaměstnance

Publikace detail

Katedry

Ústavy a pracoviště

Jak nás najdete?

Služby

Často hledáte